0.00Open0.03Pre Close0 Volume134 Open Interest2.50Strike Price0.00Turnover668.49%IV847.57%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.2280Delta0.7503Gamma8.91Leverage Ratio-0.0033Theta0.0000Rho2.03Eff Leverage0.0002Vega
Cara Therapeutics Stock Discussion
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
Cara Therapeutics announced disappointing results from Part A of their KOURAGE-1 study, evaluating oral difelikefalin for notalgia paresthetica (NP). The drug did not show meaningful clinical benefit over placebo at any dose, leading the company to discontinue the clinical program in NP. The Phase 2/3 trial involved 214 patients, and despite the...
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes30/04/2024 09:00AM ET
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic a...
still here?
Small position to start. I'll swing this one.
Potential to go higher, but will need to break 4.80 and hold above 4.60. Depending on how it does today, this could be a swing play
No comment yet